Amedeo Smart

Free Medical Literature Service


 

Amedeo

Hepatitis C

  Free Subscription

Articles published in
J Hepatol
    May 2024
  1. SHIHA G, Mikhail N, Soliman R
    Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients following SVR and its comparison with GES score.
    J Hepatol. 2024 May 15:S0168-8278(24)00348-9. doi: 10.1016/j.jhep.2024.
    >> Share

    April 2024
  2. KENNEDY MJ, Fernbach S, Scheel TKH
    Animal hepacivirus models for hepatitis C virus immune responses and pathology.
    J Hepatol. 2024 Apr 24:S0168-8278(23)05373-4. doi: 10.1016/j.jhep.2023.
    >> Share

  3. UNDERWOOD AP, Gupta M, Wu BR, Eltahla AA, et al
    B cell characteristics define HCV reinfection outcome.
    J Hepatol. 2024 Apr 9:S0168-8278(24)00271-X. doi: 10.1016/j.jhep.2024.
    >> Share

    March 2024
  4. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.
    J Hepatol. 2024 Mar 21:S0168-8278(24)00198-3. doi: 10.1016/j.jhep.2024.
    >> Share

  5. SHEEHAN Y, Grebely J, Lloyd AR
    Reply to: " 'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison - some issues".
    J Hepatol. 2024;80:e107-e108.
    >> Share

    January 2024
  6. HEO M, Norton BL, Pericot-Valverde I, Mehta SH, et al
    Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic Response. among People Who Inject Drugs: The HERO Study.
    J Hepatol. 2024 Jan 17:S0168-8278(23)05374-6. doi: 10.1016/j.jhep.2023.
    >> Share

  7. HACHICHA-MAALEJ N, Collins IJ, Ades AE, Scott K, et al
    Corrigendum to "Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine" [J Hepatol (2023) 937-946].
    J Hepatol. 2024 Jan 4:S0168-8278(23)05367-9. doi: 10.1016/j.jhep.2023.
    >> Share

  8. THOMPSON LA, Charlton CL
    Evaluation and comparison of risk-based and universal HCV screening programs.
    J Hepatol. 2024 Jan 3:S0168-8278(24)00005-9. doi: 10.1016/j.jhep.2023.
    >> Share

    November 2023
  9. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation" [J Hepatol (2023) 645-656].
    J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023.
    >> Share

    August 2023
  10. DAI CY, Batsaikhan B, Huang CF
    'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison: some issues.
    J Hepatol. 2023 Aug 8:S0168-8278(23)05050-X. doi: 10.1016/j.jhep.2023.
    >> Share

    July 2023
  11. MARTIN MT, Patel S, Chacra W
    Pellet-based hepatitis C virus treatment with glecaprevir/pibrentasvir: a case report of an adult with short bowel syndrome.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04997-8. doi: 10.1016/j.jhep.2023.
    >> Share

    June 2023
  12. MINAMI T, Sato M, Toyoda H, Yasuda S, et al
    Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
    J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
    >> Share

  13. THOMPSON LA, Plitt SS, Doucette K, Coffin CS, et al
    Evaluation and comparison of risk-based and universal prenatal HCV screening programs in Alberta, Canada.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00419-1. doi: 10.1016/j.jhep.2023.
    >> Share

  14. PATEL S, Moser A, Domingo H
    Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs.
    J Hepatol. 2023 Jun 2:S0168-8278(23)00347-1. doi: 10.1016/j.jhep.2023.
    >> Share

    May 2023
  15. DENG H, Pan Y
    The influence of invasive procedures on acute HBV and HCV infections.
    J Hepatol. 2023 May 10:S0168-8278(23)00326-4. doi: 10.1016/j.jhep.2023.
    >> Share

    April 2023
  16. KONDILI LA, Rumi MG, Craxi A
    Hospital HCV elimination in addition to universal precautions could reduce incidence and infection burden in Italy.
    J Hepatol. 2023 Apr 28:S0168-8278(23)00310-0. doi: 10.1016/j.jhep.2023.
    >> Share

  17. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation.
    J Hepatol. 2023 Apr 28:S0168-8278(23)00309-4. doi: 10.1016/j.jhep.2023.
    >> Share

  18. SHEEHAN Y, Cunningham EB, Cochrane A, Byrne M, et al
    A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study.
    J Hepatol. 2023 Apr 26:S0168-8278(23)00242-8. doi: 10.1016/j.jhep.2023.
    >> Share

  19. EL-KASSAS M, Emadeldeen M, Hassany M, Esmat G, et al
    A randomized controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00234-9. doi: 10.1016/j.jhep.2023.
    >> Share

  20. CROUCHET E, Baumert TF
    Unraveling the role of the liver myeloid compartment during hepatitis C virus cure.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00239-8. doi: 10.1016/j.jhep.2023.
    >> Share

    March 2023
  21. TOSETTI G, Degasperi E, Farina E, Primignani M, et al
    Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis?
    J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023.
    >> Share

  22. CUI A, Li B, Wallace MS, Gonye ALK, et al
    Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis.
    J Hepatol. 2023 Mar 25:S0168-8278(23)00190-3. doi: 10.1016/j.jhep.2023.
    >> Share

  23. CAMINADA S, Mele A, Ferrigno L, Alfonsi V, et al
    Risk of parenterally transmitted hepatitis following exposure to invasive procedures in Italy: SEIEVA surveillance 2000-2021.
    J Hepatol. 2023 Mar 17:S0168-8278(23)00177-0. doi: 10.1016/j.jhep.2023.
    >> Share

  24. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    Corrigendum to 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia' (J Hepatol [2023] 260-270).
    J Hepatol. 2023 Mar 8:S0168-8278(23)00109-5. doi: 10.1016/j.jhep.2023.
    >> Share

    January 2023
  25. BURGER D, Aktas H, de Knegt R
    Sustained virological response in an HCV-infected patient on an enzyme-inducing anti-epileptic agent despite undetectable trough plasma levels of velpatasvir.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00027-2. doi: 10.1016/j.jhep.2023.
    >> Share

  26. MAALEJ NH, Collins IJ, Ades AE, Scott K, et al
    Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00014-4. doi: 10.1016/j.jhep.2022.
    >> Share

    December 2022
  27. EUROPEAN ASSOCIATION FOR THE S
    Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series(') [J Hepatol 73 (2020) 1170-1218].
    J Hepatol. 2022 Dec 1:S0168-8278(22)03142-7. doi: 10.1016/j.jhep.2022.
    >> Share

    November 2022
  28. VAN DER PLUIJM RW, Smits LP, Rebers SP, Schinkel J, et al
    Unmasking of a hepatitis c genotype 3a/1b dual infection in an individual treated with elbasvir/ grazoprevir.
    J Hepatol. 2022 Nov 23:S0168-8278(22)03310-4. doi: 10.1016/j.jhep.2022.
    >> Share

    October 2022
  29. TSAI PC, Kuo HT, Hung CH, Tseng KC, et al
    Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    J Hepatol. 2022 Oct 5. pii: S0168-8278(22)03129.
    >> Share

    September 2022
  30. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    National trends in retreatment of HCV due to reinfection or treatment failure in Australia.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03118.
    >> Share

  31. OLTMANNS C, Liu Z, Mischke J, Tauwaldt J, et al
    Reverse Inflammaging: Long-term effects of HCV cure on biological age.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03115.
    >> Share

  32. SEMMLER G, Lens S, Meyer EL, Baiges A, et al
    Non-invasive tests for clinically significant portal hypertension after HCV cure.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03056.
    >> Share

    August 2022
  33. DIETZ J, Mullhaupt B, Buggisch P, Graf C, et al
    Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
    J Hepatol. 2022 Aug 25. pii: S0168-8278(22)03016.
    >> Share

    July 2022
  34. SEMMLER G, Meyer EL, Mandorfer M
    De-novo-HCC risk stratification after HCV-cure: All roads lead to Rome?
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02944.
    >> Share

  35. KARIMI-SARI H, Rezaee-Zavareh MS, Falade-Nwulia O, Lim JK, et al
    Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02922.
    >> Share

    May 2022
  36. KUSHNER T, Djerboua M, Biondi MJ, Feld JJ, et al
    Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00331.
    >> Share

  37. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
    Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029].
    J Hepatol. 2022 May 14. pii: S0168-8278(22)00247.
    >> Share

  38. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557].
    J Hepatol. 2022 May 9. pii: S0168-8278(22)00248.
    >> Share

  39. SEMMLER G, Mandorfer M
    Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.
    >> Share

  40. BHAGAT N, Verma N, Singh V
    HCC prediction post SVR in HCV patients: many tools yet limited generalizability!
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00264.
    >> Share

    March 2022
  41. NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
    Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.
    >> Share

  42. TORGERSEN J, Taddei TH, Lo Re V 3rd
    Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.
    >> Share

    February 2022
  43. MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
    Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
    >> Share

  44. LESLIE J, Geh D, Elsharkawy AM, Mann DA, et al
    Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00076.
    >> Share

    January 2022
  45. GALLARD C, Lebsir N, Khursheed H, Reungoat E, et al
    Heparanase is upregulated by HCV and favors its replication.
    J Hepatol. 2022 Jan 24. pii: S0168-8278(22)00021.
    >> Share

  46. WONG YJ, Nguyen MH
    Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.
    >> Share

  47. PIHL AF, Feng S, Offersgaard A, Alzua GP, et al
    Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02303.
    >> Share

    December 2021
  48. BEAUMONT E, Larochette V, Preisser L, Miot C, et al
    IL-26 inhibits hepatitis C virus replication in hepatocytes.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02253.
    >> Share

  49. SEMMLER G, Meyer EL, Kozbial K, Schwabl P, et al
    HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02234.
    >> Share

    November 2021
  50. SANDUZZI-ZAMPARELLI M, Marino Z, Lens S, Sapena V, et al
    Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
    J Hepatol. 2021 Nov 29. pii: S0168-8278(21)02228.
    >> Share

    October 2021
  51. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    J Hepatol. 2021 Oct 8. pii: S0168-8278(21)02103.
    >> Share

  52. MALLET V, Beeker N, Bouam S, Sogni P, et al
    Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.
    J Hepatol. 2021;75:848-855.
    >> Share

  53. WANG GP, Schnell GL, Kort JJ, Sidhu GS, et al
    Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
    J Hepatol. 2021;75:820-828.
    >> Share

    September 2021
  54. CACOUB P, Comarmond C, Vieira M, Regnier P, et al
    HCV-related lymphoproliferative disorders in the direct-acting antivirals era: from mixed cryoglobulinemia to B-cell lymphoma.
    J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02084.
    >> Share

  55. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
    Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
    >> Share

    August 2021
  56. DO CARMO RF, de Souza CDF
    Impact of the COVID-19 pandemic on hepatitis C diagnosis in Brazil: Is the global hepatitis C elimination strategy at risk?
    J Hepatol. 2021 Aug 23. pii: S0168-8278(21)01999.
    >> Share

    July 2021
  57. BORGIA SM, Shafran SD
    Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".
    J Hepatol. 2021 Jul 19. pii: S0168-8278(21)01908.
    >> Share

  58. MONTALDO C, Terri M, Riccioni V, Battistelli C, et al
    Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response.
    J Hepatol. 2021 Jul 13. pii: S0168-8278(21)01901.
    >> Share

    June 2021
  59. MARCOS-FOSCH C, Cabezas J, Crespo J, Buti M, et al
    Anti-epileptic drugs and hepatitis C therapy: real world experience.
    J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00414.
    >> Share

  60. JANJUA NZ, Wong S, Abdia Y, Jeong D, et al
    Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
    J Hepatol. 2021 Jun 4. pii: S0168-8278(21)00401.
    >> Share

  61. SARRAZIN C
    Treatment failure with DAA therapy: Importance of resistance.
    J Hepatol. 2021;74:1472-1482.
    >> Share

    May 2021
  62. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    >> Share

  63. HUANG CF, Wei YJ, Wu YT, Chiu YW, et al
    Real world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00351.
    >> Share

  64. MATTHEWS GV, Bhagani S, Van der Valk M, Rockstroh J, et al
    Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
    J Hepatol. 2021 May 20. pii: S0168-8278(21)00336.
    >> Share

  65. SHAH R, Ahovegbe L, Niebel M, Shepherd J, et al
    Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.
    J Hepatol. 2021 May 8. pii: S0168-8278(21)00310.
    >> Share

  66. CRESPO J, Diaz-Gonzalez A, Cabezas J
    HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?
    J Hepatol. 2021 May 7. pii: S0168-8278(21)00308.
    >> Share

  67. REIG M, Cabibbo G
    Antiviral therapy in the palliative setting of HCC (BCLC-B and -C).
    J Hepatol. 2021;74:1225-1233.
    >> Share

    April 2021
  68. DIETZ J, Sarrazin C
    Reply to "glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00252.
    >> Share

  69. LLAMOSAS-FALCON L, Shield KD, Gelovany M, Hasan OSM, et al
    Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis.
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00253.
    >> Share

  70. SONNEVELD MJ, Veldhuijzen IK, van de Laar T, Op de Coul ELM, et al
    DECREASE IN VIRAL HEPATITIS DIAGNOSES DURING THE COVID-19 PANDEMIC IN THE NETHERLANDS.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00250.
    >> Share

  71. DIETZ J, Di Maio VC, de Salazar A, Merino D, et al
    Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
    J Hepatol. 2021;74:801-810.
    >> Share

    March 2021
  72. CRESPO J, Lazarus JV, Iruzubieta P, Garcia F, et al
    Let's leverage SARS-CoV2 vaccination to screen for hepatitis C screening in Spain, in Europe, around the world.
    J Hepatol. 2021 Mar 20. pii: S0168-8278(21)00181.
    >> Share

  73. LIAO SH, Chen CL, Hsu CY, Chien KL, et al
    Long-term Effectiveness of Population-wide Multifaceted Interventions for Hepatocellular Carcinoma in Taiwan.
    J Hepatol. 2021 Mar 6. pii: S0168-8278(21)00163.
    >> Share

    February 2021
  74. MARTIN MT, Patel S, Kulik L, Chan C, et al
    Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.
    J Hepatol. 2021 Feb 27. pii: S0168-8278(21)00158.
    >> Share

  75. CAPRARU C, Feld JJ
    Remaining challenges in HCV elimination.
    J Hepatol. 2021 Feb 12. pii: S0168-8278(20)33845.
    >> Share

  76. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
    Diagnosis and management of secondary causes of steatohepatitis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
    >> Share

  77. IOANNOU GN
    HCC surveillance after SVR in patients with F3/F4 fibrosis.
    J Hepatol. 2021;74:458-465.
    >> Share

    January 2021
  78. GIACOMELLI A, Pagani G, Conti F, Bassoli C, et al
    Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in Northern Italy.
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00009.
    >> Share

  79. FAN R, Yin X, Hou J
    Reply to "External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs".
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00011.
    >> Share

  80. LIU CH, Kao JH
    Reply to: "Sofosbuvir and the risk of kidney dysfunction".
    J Hepatol. 2021;74:257-258.
    >> Share

    December 2020
  81. BUTI M, Dominguez-Hernandez R, Casado MA
    Impact of the COVID 19 Pandemic on HCV Elimination in Spain.
    J Hepatol. 2020 Dec 20. pii: S0168-8278(20)33891.
    >> Share

  82. CALVARUSO V, Craxi A
    Reply to letters to the Editor on manuscript "Hepatic benefits of HCV cure". JHEPAT-D-20-01349R1.
    J Hepatol. 2020 Dec 17. pii: S0168-8278(20)33888.
    >> Share

  83. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33773.
    >> Share

  84. ZEUZEM S
    Introducing the HCV miniseries.
    J Hepatol. 2020;73:1306.
    >> Share

  85. BAUMERT TF
    The Nobel Prize in Medicine 2020 for the Discovery of Hepatitis C Virus: Transforming Hepatology.
    J Hepatol. 2020;73:1303-1305.
    >> Share

  86. NEGRO F
    Residual risk of liver disease after hepatitis C virus eradication.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33827.
    >> Share

    November 2020
  87. KUSHNER T, Reau N
    Changing epidemiology, implications, and recommendations for Hepatitis C in Women of Childbearing Age and During Pregnancy.
    J Hepatol. 2020 Nov 25. pii: S0168-8278(20)33814.
    >> Share

  88. KRASSENBURG LAP, Maan R, Ramji A, Manns MP, et al
    Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33805.
    >> Share


  89. Reply to: "EASL recommendations on treatment of hepatitis C: Final update of the series - some issues".
    J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33741.
    >> Share

  90. DAI CY, Chuang WL, Yu ML
    EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues.
    J Hepatol. 2020 Nov 19. pii: S0168-8278(20)33693.
    >> Share

  91. WEINFURTNER K, Reddy KR
    Hepatitis C Viremic Organs in Solid Organ Transplantation.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33767.
    >> Share

  92. AQEL B, Wijarnpreecha K, Pungpapong S, Taner CB, et al
    Outcomes following transplantation of HCV-seropositive livers to HCV-seronegative recipients.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33754.
    >> Share

  93. ZANETTO A, Simioni P, Russo FP
    Hepatic benefits of HCV cure: don't forget coagulation!
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33747.
    >> Share

    October 2020
  94. SHIHA G, Mikhail N, Soliman R
    External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33688.
    >> Share

  95. CRESPO J, Diaz-Gonzalez A, Iruzubieta P, Llerena S, et al
    SARS-CoV-2 massive testing: a window of opportunity to catch up with HCV elimination.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33679.
    >> Share

    September 2020
  96. THIMME R
    T cell immunity to hepatitis C virus: lessons for a prophylactic HCV vaccine.
    J Hepatol. 2020 Sep 28. pii: S0168-8278(20)33665.
    >> Share

  97. VIRZI A, Roca Suarez AA, Lupberger J
    Interferon revisited: Peering behind the lines of antiviral defense.
    J Hepatol. 2020;73:496-498.
    >> Share

    August 2020
  98. CALVARUSO V, Bruix J
    Towards personalized screening for hepatocellular carcinoma: still not there.
    J Hepatol. 2020 Aug 5. pii: S0168-8278(20)30405.
    >> Share

    May 2020
  99. SAPENA V, Rios J, Torres F, Marino Z, et al
    Reply to: "The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut".
    J Hepatol. 2020;72:1036-1037.
    >> Share

  100. INNES HA, McDonald SA, Barclay ST, Irving WL, et al
    The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut.
    J Hepatol. 2020;72:1034-1035.
    >> Share

    February 2020
  101. VIBERT E, Schwartz M, Olthoff KM
    Advances in resection and transplantation for hepatocellular carcinoma.
    J Hepatol. 2020;72:262-276.
    >> Share

  102. SINGAL AG, Lampertico P, Nahon P
    Epidemiology and surveillance for hepatocellular carcinoma: New trends.
    J Hepatol. 2020;72:250-261.
    >> Share

    October 2019
  103. LAPOINTE-SHAW L, Austin PC, Chung H, Sander B, et al
    Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis.
    J Hepatol. 2019 Oct 21. pii: S0168-8278(19)30387.
    >> Share

    September 2019
  104. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
    >> Share

    July 2019
  105. AVERHOFF F, Lazarus JV, Sergeenko D, Colombo M, et al
    Excellence in Viral Hepatitis Elimination - Lessons from Georgia.
    J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30398.
    >> Share

    June 2019
  106. YAU T, Hsu C, Kim TY, Choo SP, et al
    Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis.
    J Hepatol. 2019 Jun 6. pii: S0168-8278(19)30300.
    >> Share

    March 2019
  107. FONTAINE H, Alric L, Labreuche J, Legendre B, et al
    Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
    J Hepatol. 2019 Mar 9. pii: S0168-8278(19)30020.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016